Navigation Links
National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos

(PRWEB) June 23, 2012

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a woman who suffers from bladder cancer, allegedly due to Actos. The suit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Co. as Defendants. The complaint was filed on June 14th in the U.S. District Court for the Western District of Louisiana (Case No. 6:12-cv-1701) and is currently pending in the Actos multidistrict litigation. Proceedings are centralized before Judge Rebecca F. Doherty, and Jerrold S. Parker, founding partner of Parker Waichman, has been appointed to the Plaintiff’s Steering Committee. [;

According to the complaint, the Plaintiff took Actos from 2004 and 2007; she developed bladder cancer around April 2006. The lawsuit alleges that Actos caused the bladder cancer, claiming that the Defendants were aware of this risk but did not inform the public. As a result of their negligent and/or fraudulent actions, the lawsuit is alleging severe mental and physical pain and suffering, past and future permanent injuries and emotional distress, economic loss due to medical expenses and living related expenses as a result of a new lifestyle. The suit also claims loss of consortium on behalf of the Plaintiff’s husband.

Actos is a medication approved to treat type 2 diabetes, a condition where the body fails to produce an adequate amount of insulin or does not utilize insulin efficiently. As a result, the body is unable to break down glucose for energy. Actos is intended to treat this problem by increasing the body’s sensitivity to insulin.

Actos was originally launched by Takeda and Eli Lilly. According to the lawsuit, Takeda announced the end of this joint venture in April 2006.

Actos was suspended in France and Germany last June, after a study funded by the French Medicines Agency found that using Actos for one year was linked to an increased risk of bladder cancer in men. Days later, the U.S. Food and Drug Administration (FDA) announced that the Warnings and Precautions section of the label for Actos and other pioglitazone-containing medications would be changed to address a potential increased risk of bladder cancer. According to the agency’s Safety Announcement, use of Actos for one year was linked to an increased risk of 40 percent. This past April, Health Canada made similar changes to the Actos label. [;

Recent studies continue to support the link between the diabetes drug and bladder cancer. Late last month, Canadian researchers found that use of Actos for two years was associated with a two-fold increased risk. The study was published in the British Medical Journal. []

Parker Waichman LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm's Actos injury page at Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

For more information regarding Actos side effect lawsuits and Parker Waichman LLP, please visit or call 1-800-LAW-INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. MU receives national award for using mind-body approach to improve health
2. International breast health global summit will focus on supportive care and quality of life
3. International conference to explore health of descendants of transatlantic slave trade
4. National poll: Low cost, lifesaving services missing from most older patients health care
5. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
6. Kessler Foundation researchers present at first International Congress on Cognition in MS
7. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
8. Georgetown physician leads national resveratrol study for Alzheimers disease
9. National initiative launched to change the way biology departments approach undergraduate education
10. Boston researcher, surgical oncologist receives national award
11. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
Post Your Comments:
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on a couch can actually ... conceived of this design due to personal experience with a bad back," he said. ... and convenience, as well as increases support. It also makes it easier to eat, ...
(Date:11/28/2015)... Viejo, CA (PRWEB) , ... November 28, 2015 , ... ... new fully customizable media panels to choose from, the possibilities are endless. Users have ... and more. With the ProPanel: Pulse masking effects, users are sure to get heads ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... they are handling security in light of the recent terrorist attacks in Paris, other ... to stop an attack from reaching U.S. soil. Especially around special events that may ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
Breaking Medicine Technology: